Squamous cell carcinoma of the head and neck (SCCHN) is a devastating disease that has a dismal prognosis, despite aggressive surgical and adjuvant therapy. The average estimated overall survival for patients is approximately 50% at 5 years (NIDCR.GOV). The high mortality rate demonstrates that current therapeutic strategies are not adequate. In an effort to improve the outcomes for these patients, genetic analysis of SCCHN has been used to identify potential novel therapeutic targets. One of the most commonly altered genes in this malignancy is the calcium activated chloride channel TMEM16A/ANO1. TMEM16A is amplified in 30% of SCCHN, and overexpression is correlated with poor oncologic outcomes in several cancer types. Our recent data demonstrates that TMEM16A expression abrogates cisplatin-induced apoptosis. It is therefore likely that TMEM16A plays a cytoprotective role in cancer cells. How TMEM16A improves the survival and resistance of cancer cells to therapeutic interventions is unknown. Sequestration of the cancer drugs and other toxins by the lysosomes followed by their expulsion through the process of lysosomal exocytosis has emerged as a mechanism that enhances drug resistance of cancer cells. We find that TMEM16A expression is associated with increased lysosomal acidification, biogenesis and exocytosis. We propose that TMEM16A over-expressing cells are more efficient in the expulsion of cytotoxic drugs than wild-type cells. We also postulate that TMEM16A overexpressing tumors are more likely to upregulate lysosomal flux, and therefore contribute to oncogenesis and resistance to cytotoxic chemotherapy. This is a groundbreaking concept, since it identifies a new function of a novel ion channel and a new paradigm in cancer pathology and suggests a new approach to cancer treatment. During this project, we will identify the mechanism of the TMEM16A-dependent cytoprotective upregulation of the lysosomal throughput and sequestration/expulsion of cytotoxic drugs. We will test this hypothesis using human tissues and patient-derived xenograft models. Finally we will test our concepts using the mouse model of human head and neck tumors and the new approaches specifically aimed at suppressing lysosomal biogenesis and exocytosis using repurposed antimalarial drugs. The results for these studies can be directly translated to clinical investigations, by combining anti-lysosomal drugs with conventional cytotoxic agents, noth of which are FDA-approved agents.

Public Health Relevance

Aggressive surgical resection followed by adjuvant therapy consisting of (chemo)radiation is the mainstay of treatment for squamous cell carcinoma of the head and neck (SCCHN). Despite these treatments, SCCHN is a devastating disease that portends an overall 5-year survival of only ~50%. There is therefore a need to identify novel strategies and drug combinations to treat SCCHN.

National Institute of Health (NIH)
National Institute of Dental & Craniofacial Research (NIDCR)
Research Project (R01)
Project #
Application #
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Lumelsky, Nadya L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code